VCZ en es it fr

VCZ Brand names, VCZ Analogs

VCZ Brand Names Mixture

  • No information avaliable

VCZ Chemical_Formula


VCZ RX_link

VCZ fda sheet


VCZ msds (material safety sheet)


VCZ Synthesis Reference

No information avaliable

VCZ Molecular Weight

349.311 g/mol

VCZ Melting Point

127 - 130 oC

VCZ H2O Solubility


VCZ State




VCZ Dosage Forms

Tablet; Oral suspension; IV injection

VCZ Indication

For the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.

VCZ Pharmacology

Voriconazole is a triazole antifungal agent indicated for use in the treatment of fungal infections including invasive aspergillosis, esophageal candidiasis, and serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani. Fungal plasma membranes are similar to mammalian plasma membranes, differing in having the nonpolar sterol ergosterol, rather than cholesterol, as the principal sterol. Membrane sterols such as ergosterol provide structure, modulation of membrane fluidity, and possibly control of some physiologic events. Voriconazole effects the formation of the fungal plasma membrane by indirectly inhibiting the biosynthesis of ergosterol. This results in plasma membrane permeability changes and inhibition of growth.

VCZ Absorption

The oral bioavailability is estimated to be 96% (CV 13%).

VCZ side effects and Toxicity

The minimum lethal oral dose in mice and rats was 300 mg/kg (equivalent to 4 and 7 times the recommended maintenance dose (RMD), based on body surface area). At this dose, clinical signs observed in both mice and rats included salivation, mydriasis, titubation (loss of balance while moving), depressed behavior, prostration, partially closed eyes, and dyspnea. Other signs in mice were convulsions, corneal opacification and swollen abdomen.

VCZ Patient Information

VCZ Organisms Affected

Yeast and other fungi